Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LRMR
stocks logo

LRMR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.546
+21.26%
--
--
-0.458
-0.5%
--
--
-0.421
+2.8%
Estimates Revision
The market is revising No Change the revenue expectations for Larimar Therapeutics, Inc. (LRMR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.60%.
EPS Estimates for FY2025
Revise Upward
up Image
+12.55%
In Past 3 Month
Stock Price
Go Down
down Image
-6.60%
In Past 3 Month
Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 18.00 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 18.00 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.680
sliders
Low
7.00
Averages
18.00
High
26.00
Current: 3.680
sliders
Low
7.00
Averages
18.00
High
26.00
Baird
Joel Beatty
Outperform
downgrade
$10 -> $7
2025-09-30
Reason
Baird
Joel Beatty
Price Target
$10 -> $7
2025-09-30
downgrade
Outperform
Reason
Baird analyst Joel Beatty lowered the firm's price target on Larimar Therapeutics to $7 from $10 and keeps an Outperform rating on the shares. The firm updated its model to reflect increased safety and regulatory risk following the company's Nomla update.
Citizens JMP
Jonathan Wolleben
Outperform
downgrade
$22 -> $18
2025-08-15
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$22 -> $18
2025-08-15
downgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on Larimar Therapeutics to $18 from $22 and keeps an Outperform rating on the shares. Larimar will have new open-label data for nomlabofusp in September, which should provide more confidence in the Friedreich's ataxia candidate, the analyst tells investors in a research note.
Citi
Buy
maintain
$14
2025-06-24
Reason
Citi
Price Target
$14
2025-06-24
maintain
Buy
Reason
Citi views yesterday's selloff in shares of Larimar Therapeutics as a buying opportunity. Larimar announced that the FDA recommended the safety database for nomlabofusp include at least 30 patients with continuous exposure for six months, including a subset of at least 10 patients for one year, with the large majority receiving the 50mg dose, the analyst tells investors in a research note. The firm says that with full FDA alignment in hand, Larimar has a clear path to application submission, which is now guided for Q2 of 2026 versus the second half of 2025 previously, to allow for additional time to collect one year of safety follow-up for patients. Citi keeps a Buy rating on the shares with a $14 price target.
Wedbush
Outperform
to
NULL
downgrade
$17 -> $15
2025-06-24
Reason
Wedbush
Price Target
$17 -> $15
2025-06-24
downgrade
Outperform
to
NULL
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$15 → $16
2025-03-25
Reason
HC Wainwright & Co.
Edward White
Price Target
$15 → $16
2025-03-25
Maintains
Strong Buy
Reason
Baird
Joel Beatty
Buy
Maintains
$13 → $10
2025-03-25
Reason
Baird
Joel Beatty
Price Target
$13 → $10
2025-03-25
Maintains
Buy
Reason
Baird lowered the firm's price target on Larimar Therapeutics to $10 from $13 and keeps an Outperform rating on the shares. Th efirm updated its model following Q4 results which showed the FDA is open to Skin FXN as a surogate endpoint with a BLA planned by year-end 2025.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Larimar Therapeutics Inc (LRMR.O) is -2.01, compared to its 5-year average forward P/E of -3.67. For a more detailed relative valuation and DCF analysis to assess Larimar Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.67
Current PE
-2.01
Overvalued PE
-1.83
Undervalued PE
-5.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.29
Undervalued EV/EBITDA
-2.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LRMR News & Events

Events Timeline

(ET)
2025-11-05
07:32:54
Larimar Therapeutics projects funding to last through the fourth quarter of 2026.
select
2025-11-05
07:31:56
Larimar Therapeutics Announces Q3 Earnings Per Share of 61 Cents, Exceeding Consensus Estimate of 42 Cents
select
2025-09-29 (ET)
2025-09-29
07:14:12
Larimar Therapeutics Shares Progress on Nomlabofusp Program for FA
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
12-03Benzinga
Three Health Care Stocks Poised for Significant Gains This December

  • Oversold Stocks Opportunity: The health care sector has several oversold stocks, identified by a Relative Strength Index (RSI) below 30, indicating potential buying opportunities for undervalued companies.

  • Larimar Therapeutics Inc: The company reported a wider-than-expected quarterly loss, with its stock falling 20% over the past month and an RSI of 29.9, closing at $3.12.

  • Perrigo Company PLC: Perrigo's mixed financial results led to a 34% stock decline in the past month, with an RSI of 29.9, closing at $13.61, despite gaining market share in several categories.

  • ORIC Pharmaceuticals Inc: After a recent coverage initiation with an Outperform rating, ORIC's stock fell 16% over the past month, with an RSI of 29.6, closing at $10.65.

[object Object]
Preview
7.0
10-29Globenewswire
LRMR Investors Can Participate in Larimar Therapeutics, Inc. Fraud Investigation Led by Schall Law Firm

  • Investigation Announcement: The Schall Law Firm is investigating claims against Larimar Therapeutics, Inc. for potential violations of securities laws related to misleading statements and undisclosed information.

  • Study Results and Impact: Larimar reported "positive" data from a study on Nomlabofusp for Friedreich's Ataxia but revealed that seven participants experienced severe allergic reactions, leading to a significant drop of over 33.6% in the company's stock price.

  • Shareholder Rights: The firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations to discuss their rights.

  • Law Firm's Focus: The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, emphasizing its commitment to shareholder rights litigation.

[object Object]
Preview
7.0
10-23PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Larimar Therapeutics, Inc. and its officers or directors, urging affected investors to reach out for assistance.

  • Study Data Release: On September 29, 2025, Larimar released data from a study on Nomlabofusp for Friedreich's Ataxia, which, despite being labeled "positive," revealed severe allergic reactions in seven participants.

  • Stock Price Impact: Following the announcement of the study data, Larimar's stock price dropped significantly by 33.66%, closing at $3.38 per share.

  • Pomerantz LLP Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial damages awards for class members.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Larimar Therapeutics Inc (LRMR) stock price today?

The current price of LRMR is 3.68 USD — it has increased 6.05 % in the last trading day.

arrow icon

What is Larimar Therapeutics Inc (LRMR)'s business?

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

arrow icon

What is the price predicton of LRMR Stock?

Wall Street analysts forecast LRMR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRMR is 18.00 USD with a low forecast of 7.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Larimar Therapeutics Inc (LRMR)'s revenue for the last quarter?

Larimar Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Larimar Therapeutics Inc (LRMR)'s earnings per share (EPS) for the last quarter?

Larimar Therapeutics Inc. EPS for the last quarter amounts to -0.61 USD, increased 154.17 % YoY.

arrow icon

What changes have occurred in the market's expectations for Larimar Therapeutics Inc (LRMR)'s fundamentals?

The market is revising No Change the revenue expectations for Larimar Therapeutics, Inc. (LRMR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.60%.
arrow icon

How many employees does Larimar Therapeutics Inc (LRMR). have?

Larimar Therapeutics Inc (LRMR) has 65 emplpoyees as of December 05 2025.

arrow icon

What is Larimar Therapeutics Inc (LRMR) market cap?

Today LRMR has the market capitalization of 315.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free